NVAX Novavax Inc.

1.43
+0.07  (5%)
Previous Close 1.36
Open 1.38
Price To book -5.96
Market Cap 448471196
Shares 313,616,221
Volume 1,712,061
Short Ratio 10.03
Av. Daily Volume 4,388,184

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 initiation announced September 19, 2017 with data due 4Q 2017.
NanoFlu vaccine
Influenza
Phase 2 safety and immunogenicity data released July 24, 2017 - efficacy trial to be initiated 2018.
RSV F Vaccine immunogenicity trial
Respiratory Syncytial Virus (RSV) in older adults
Phase 3 initiated December 2015. Expected to take 2-4 years to complete
RSV vaccine - prepare trial
Respiratory Syncytial Virus (RSV) in healthy pregnant women - protect infants via maternal immunization
Phase 3 released September 15, 2016 did not demonstrate efficacy.
RSV vaccine - Resolve trial
Respiratory Syncytial Virus (RSV) in older adults
Phase 2 data released September 15, 2016.
RSV F Vaccine rollover trial
Respiratory Syncytial Virus (RSV) in older adults
Further Phase 2 trials planned
Seasonal Influenza Vaccine
Seasonal Flu

SEC Filings

  1. 8-K - Current report 171183838
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171183784
  3. 8-K - Current report 171137125
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 171078374
  5. S-8 - Securities to be offered to employees in employee benefit plans 171018150
  6. 8-K - Current report 171017859
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 171014966
  8. 8-K - Current report 17982867
  9. 8-K - Current report 17916461
  10. 8-K - Current report 17826366